THCX News and Press, Spinnaker ETF Series The Cannabis From 09/30/21

Cannabis marketplace Leafly will go public via SPAC with Merida Merger Corp. CEO Yoko Miyashita joins us to discuss remaining in compliance, showcasing cannabinoids beyond strain names or indica/sativa. COVID-19’s impact; predictions for the cannabis industry. For fur...

Foothill Capital Management is converting its Cannabis Growth Fund (CANIX) mutual fund into the Cannabis Growth ETF (NYSEARCA:BUDX). The move comes as the traditional mutual fund found itself outperforming many Cannabis ETFs, yet not garnering the amount of fund flows one would expect. BUDX h...

The U.S. House of Representatives approved a bill enabling banks to do business with cannabis companies without fear of penalty, Bloomberg reports. The so-called SAFE Banking Act would be a boon for marijuana companies, which have so-far used to deal in cash because of federal restrictions, w...

InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going forward. ...

One of the most interesting things about these stocks is that, due to the fact that they don’t trade on a major U.S. exchange, many investors can’t or simply won’t buy them. As such, it may now finally be time to get bullish on green bud. The stocks have been abso...

RIV Capital, formerly known as Canopy Rivers, is an investment and acquisition company in the cannabis industry. CEO Narbé Alexandrian joins us to discuss moving on from Canopy Growth and why it views the US as the holy grail of cannabis. Strategic investment from Scotts Mira...

180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitati...

InterCure is the most profitable cannabis company outside North America and recently uplisted to Nasdaq. Israel's former Prime Minister, Chairman Ehud Barak and CEO Alex Rabinovitch join the podcast to discuss Israel's cannabis landscape and what investors can expect going forward. ...

180 Life Sciences' Prof. Sir Marc Feldmann, who co-founded ATNF with cannabis trailblazer Prof. Raphael Mechoulam, joins the podcast with Dr. Jonathan Rothbard, Chief Science Officer. Focusing on pain and inflammation space. Aiming for FDA approval. Human clinical trials. Limitati...

Tim Seymour returns to the podcast to discuss cannabis investors getting more sophisticated as the industry grows up. Holding management teams more accountable, multiple quarters of execution, profitability as a relative term. Macro picture is both tremendously promising and frust...